中图分类号：
R737.9
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] FRANCIS PA,PAGANI O,FLEMING GF,et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer[J].N Engl J Med, 2018, 379(2):122-137.
[2] KIM HA,LEE JW,NAM SJ,et al. Adding Ovarian suppression to tamoxifen for premenopausal breast cancer:a randomized phase Ⅲ trial[J].J Clin Oncol, 2020, 38(5):434-443.
[3] PAGANI O,FRANCIS PA,FLEMING GF,et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women:results from TEXT and SOFT[J]. J Clin Oncol, 2020, 38(12):1293-1303.
[4] MOORE HC,UNGER JM,PHILLIPS KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J].N Engl J Med, 2015, 372(10):923-932.
[5] AGUILAR-ROJAS A,PEREZ-SOLIS MA,MAYA-NUNEZ G. The gonadotropin-releasing hormone system:Perspectives from reproduction to cancer(Review)[J]. Int J Oncol, 2016, 48(3):861-868.
[6] MERTENS-WALKER I,BAXTER RC,MARSH DJ. Gonadotropin signalling in epithelial ovarian cancer[J]. Cancer Lett, 2012, 324(2):152-159.
[7] WU HM, WANG HS, HUANG HY, et al.Gonadotropin-releasing hormone type II(GnRH-II)agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase(MAPK)-dependent activation of matrix metalloproteinase(MMP) -2[J].BMC Cancer, 2013, 13:300.
[8] EMONS G,GRUNDKER C,GUNTHERT AR,et al. GnRH antagonists in the treatment of gynecological and breast cancers[J]. Endocr Relat Cancer,2003,10(2):291-299.
[9] SVIRIDONOV L,DOBKIN-BEKMAN M,SHTERNTAL B, et al. Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines[J].Mol Cell Endocrinol, 2013, 369(1-2):107-118.
[10] TIEVA A, STATTIN P, WIKSTROM P, et al. Gonadotropin-releasing hormone receptor expression in the human prostate[J].Prostate, 2001, 47(4):276-284.
[11] SUO L,CHANG X,XU N, et al. The Anti-proliferative activity of GnRH through downregulation of the Akt/ERK pathways in pancreatic cancer[J]. Front Endocrinol (Lausanne), 2019, 10:370.
[12] MORETTI RM, MONTAGNANI MARELLI M, GROENINGHEN JCVAN, et al. Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells[J]. J Clin Endocrinol Metab, 2002, 87(8):3791-3797.
[13] SZEPESHAZI K, SCHALLY AV, HALMOS G.LH-RH receptors in human colorectal cancers:unexpected molecular targets for experimental therapy[J].Int J Oncol, 2007, 30(6):1485-1492.
[14] GRUNDKER C,ERNST J,REUTTER MD,et al. Effective targeted chemotherapy using AEZS-108(AN-152) for LHRH receptor-positive pancreatic cancers[J]. Oncol Rep, 2011, 26(3):629-635.
[15] AGUILAR-ROJAS A,HUERTA-REYES M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells(Review)[J]. Oncol Rep, 2009, 22(5):981-990.
[16] GRUNDKER C,VOLKER P,EMONS G. Antiproli-ferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase[J].Endocrinology, 2001, 142(6):2369-2380.
[17] GRUNDKER C,EMONS G. The role of gonadotropinreleasing hormone in cancer cell proliferation and metastasis[J].Front Endocrinol(Lausanne), 2017, 8:187.
[18] LIMONTA P, MONTAGNANI MARELLI M, MAI S, et al.GnRH receptors in cancer:from cell biology to novel targeted therapeutic strategies[J]. Endocr Rev,2012,33(5):784-811.
[19] CHEUNG LW, WONG AS. Gonadotropin-releasing hormone:GnRH receptor signaling in extrapituitary tissues[J].FEBS J, 2008, 275(22):5479-5495.
[20] FISTER S, GUNTHERT AR, AICHER B, et al.GnRH-II antagonists induce apoptosis in human endometrial, ovarian,and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax[J].Cancer Res, 2009, 69(16):6473-6481.
[21] BUCHHOLZ S, SEITZ S, SCHALLY AV, et al.Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition[J].Int J Oncol, 2009, 35(4):789-796.
[22] SCHUBERT A,HAWIGHORST T,EMONS G, et al. Agonists and antagonists of GnRH-Ⅰ and-Ⅱ reduce metastasis formation by triple-negative human breast cancer cells in vivo[J].Breast Cancer Res Treat, 2011, 130(3):783-790.
[23] GRÜNDKER C, BAUERSCHMITZ G, SCHUBERT A, et al. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH[J]. Int J Oncol,2016,48(6):2713-2721.
[24] THANGARAJAH F, MALTER W, HAMACHER S, et al. Predictors of sentinel lymph node metastases in breast cancer-radioactivity and Ki-67[J].Breast, 2016, 30:87-91.
[25] KIM HJ,YOON TI,CHAE HD,et al. Concurrent gonadotropin-releasing hormone agonist administration with chemotherapy improves neoadjuvant chemotherapy responses in young premenopausal breast cancer patients[J].J Breast Cancer, 2015, 18(4):365-370.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
上海市科委西医引导项目（17411961100）；上海市卫健委卫生行业临床研究专项（201940391）
{{custom_fund}}
PDF(5877 KB)
